Form 4: Avidity Biosciences Director Acquires Stock Options

Director Tamar Thompson acquired stock options in Avidity Biosciences, Inc. on June 13, 2024.

Summary

• Tamar Thompson, a director of Avidity Biosciences, Inc., filed a Form 4 on June 14, 2024.
• The filing reports a transaction that occurred on June 13, 2024, where Thompson acquired stock options.
• Thompson acquired 13,489 stock options with an exercise price of $39.96.
• These options vest on the earlier of the first anniversary of the grant date or the next annual meeting, contingent on continuous service on the board.
• Following the transaction, Thompson directly owns 13,490 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard transaction. The acquisition of stock options by a director is generally viewed as a positive sign, but it's a routine occurrence.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it indicates confidence from a company director.

Key Dates